Monthly gastroenterology and hepatology bulletin — November 7, 2026
Colleagues: this issue covers October 8 to November 7, 2026. The month was dominated by three meetings: the scientific sessions of the ACG Annual Scientific Meeting (Nashville, October 12–14), UEG Week 2026 (Barcelona, October 17–20), and AASLD's The Liver Meeting 2026, which was held November 5–9 in Denver. There were two relevant FDA decisions, one in hepatitis B and one in Crohn's disease. Much of the congress material comes from manufacturer press releases or medical press coverage and is not yet peer-reviewed; this is flagged in each item.
Inflammatory bowel disease and functional disorders
1. Oral icotrokinra in ulcerative colitis: randomized trial in NEJM and extension through week 76 (ANTHEM-UC)
[Clinical trial] [Congress] [Multinational]
Icotrokinra is an oral peptide that selectively blocks the interleukin-23 receptor (Johnson & Johnson). In the randomized, placebo-controlled phase 2b ANTHEM-UC trial, published in NEJM, 252 patients with moderately to severely active ulcerative colitis were randomized 1:1:1:1 to 100, 200, or 400 mg once daily or placebo. At week 12, clinical response was 63% (400 mg), 58% (200 mg), and 55% (100 mg) versus 27% with placebo (P < .001 for all three doses); with 400 mg, clinical remission was 30% versus 11% (P = .006) and endoscopic improvement 37% versus 14% (P = .002). Through week 28, serious adverse events were 0% to 5% with icotrokinra versus 10% with placebo. The extension follow-up was presented at ACG 2026: only patients with clinical response at week 28 continued, and placebo recipients stopped treatment. According to Healio's coverage, 136 patients entered the extension; the study's first author said about 60% were in remission at week 76, and 97% of patients in remission at week 76 remained corticosteroid-free.
Why it matters: it is an oral IL-23 pathway blocker with 18-month data, but it is a manufacturer-sponsored phase 2b trial and the extension is open-label, uncontrolled, and limited to responders, which favors high rates; phase 3 results and pricing will determine whether it reaches our practice.
Sources
- [Article] Abreu MT, Siegmund B, Surace L, et al. "Phase 2 trial of icotrokinra for patients with ulcerative colitis." N Engl J Med. 2026;395(15):1495-1504. DOI: 10.1056/NEJMoa2604435. https://doi.org/10.1056/NEJMoa2604435
- [Coverage] Healio, October 21, 2026. https://www.healio.com/news/gastroenterology/20261021/oral-icotrokinra-sustains-uc-response-through-76-weeks-with-an-easier-sell-to-patients
- [Coverage] HCPLive, October 13, 2026. https://www.hcplive.com/view/oral-icotrokinra-sustains-uc-response-through-76-weeks-in-anthem-uc-lte
2. FDA approves at-home subcutaneous induction of risankizumab for Crohn's disease
[Regulatory FDA] [United States]
On October 23, 2026, AbbVie announced that the FDA approved a subcutaneous induction regimen of risankizumab (Skyrizi) for adults with moderately to severely active Crohn's disease: 720 mg by on-body injector at weeks 0, 2, 4, and 8, then maintenance every 8 weeks from week 12; intravenous induction remains available. According to the release, approval rests on the phase 3 AFFIRM trial (2:1 randomization versus placebo; 65% with prior advanced therapy failure): at week 12, clinical remission was 56% versus 30% and endoscopic response 43% versus 15% (P < .001); among patients with prior failure, remission was 45% versus 31%. In AbbVie's overall week-24 analysis presented at ACG, endoscopic remission was 35.8% versus 9.1%; after week 12, treatment depended on clinical response and, according to a footnote in the release, endpoints beyond week 12 were assessed in patients who had responded to induction. According to AbbVie's approval release, the label was updated to leave pretreatment tuberculosis evaluation to clinical judgment.
Why it matters: it removes the need for infusion centers, which is practical where they are scarce, but the benefit in refractory patients is smaller; in a country with the tuberculosis incidence of the Dominican Republic, keeping tuberculosis screening is the prudent course.
Sources
- [Official release] AbbVie, October 23, 2026. https://news.abbvie.com/2026-10-23-U-S-FDA-Approves-Subcutaneous-Induction-Regimen-for-AbbVies-SKYRIZI-R-risankizumab-rzaa-for-Adults-With-Moderately-to-Severely-Active-Crohns-Disease
- [Official release] AbbVie, October 13, 2026. https://news.abbvie.com/2026-10-13-AbbVie-Presents-New-Phase-3-AFFIRM-Data-Showing-Clinical-and-Endoscopic-Outcomes-With-Subcutaneous-SKYRIZI-R-risankizumab-rzaa-in-Patients-With-Moderately-to-Severely-Active-Crohns-Disease
- [Coverage] Healio, October 23, 2026. https://www.healio.com/news/gastroenterology/20261023/fda-approves-subcutaneous-induction-regimen-of-skyrizi-for-crohns-disease
3. Antibody signatures distinguished people later diagnosed with IBD in archived samples
[Congress]
According to UEG's October 19 release, the study, presented at UEG Week 2026, included 500 individuals (200 who developed Crohn's disease, 200 who developed ulcerative colitis, and 100 age- and sex-matched healthy controls) and 2,000 serum samples taken at diagnosis and about 2, 4, and 10 years earlier, profiled against roughly 357,000 antigens using machine-learning models. The models discriminated from controls with an AUC of 0.90 for Crohn's disease and 0.84 for ulcerative colitis, and 0.85 for complicated versus uncomplicated Crohn's disease. The authors describe it as a proof of principle and say the signatures must be validated in independent, more diverse, prospectively followed populations before becoming a screening test. According to Mount Sinai, the study had been published in Gut in July 2026.
Why it matters: this is a proof of concept in archived samples and not yet a validated screening test; it has no clinical use yet but opens the door to prevention studies in at-risk individuals.
Sources
- [Official release] United European Gastroenterology (UEG), October 19, 2026. https://ueg.eu/a/391
- [Coverage] News-Medical, October 19, 2026. https://www.news-medical.net/news/20261019/Antibody-patterns-may-predict-inflammatory-bowel-disease-years-before-diagnosis.aspx
- [Official release] Mount Sinai, July 22, 2026. https://www.mountsinai.org/about/newsroom/2026/mount-sinai-study-detects-immune-changes-up-to-10-years-before-inflammatory-bowel-disease-is-diagnosed
4. Antibiotic use from childhood and irritable bowel syndrome in young adulthood
[Congress] [Sweden]
In the Swedish BAMSE birth cohort (2,853 participants), with prescriptions recorded from ages 9–11 until one year before assessment, IBS prevalence at age 24 was 10%. Any antibiotic use was associated with an OR of 1.5 (95% CI, 1.0–2.2), with a gradient by number of prescriptions (6 or more: OR 1.7; 95% CI, 1.1–2.6); 3 or more cephalosporin prescriptions were associated with an OR of 6.0 (95% CI, 1.9–18.8). Presented at UEG Week 2026 on October 19.
Why it matters: this is an observational association with wide intervals and possible confounding by indication; it supports prudent antibiotic prescribing but does not change IBS management.
Sources
- [Official release] United European Gastroenterology (UEG), October 19, 2026. https://ueg.eu/a/392
- [Official release] UEG Week 2026 (distributed by Kyodo News PR Wire), October 19, 2026. https://kyodonewsprwire.jp/release/202610198155
Liver
5. FDA approves bepirovirsen (Hibsago), the first antisense oligonucleotide approved by the agency for chronic hepatitis B
[Regulatory FDA] [United Kingdom / United States]
On October 20, 2026, the FDA approved bepirovirsen (GSK), a subcutaneous antisense oligonucleotide given for six months in combination with antiviral therapy, for adults with chronic hepatitis B without cirrhosis who have been on antivirals for at least 6 months, with suppressed HBV DNA and HBsAg ≤3,000 IU/mL measured by an FDA-authorized test. In the phase 3 B-Well 1 and 2 trials (29 countries, double-blind, placebo-controlled), functional cure, defined as suppressed HBV DNA and undetectable HBsAg 24 weeks after stopping all treatment (trial week 72), was 19% (233/1,220) versus 0% (0/614); with HBsAg ≤1,000 IU/mL it reached 26% (200/768) versus 0% (0/393). The most common adverse events were injection-site redness and pain and a transient rise in aminotransferases; the label carries a boxed warning for serious liver reactions and thrombocytopenia.
Why it matters: it opens the possibility of functional cure after finite treatment, but only one in five patients responds, the result does not justify stopping antivirals across the board, HBsAg quantification is required (scarcely available in the Dominican Republic), and cirrhosis is excluded; cost and regional access are the major unknowns.
Sources
- [Regulator] FDA, press announcement "FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment," October 20, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment
- [Official release] GSK, October 20, 2026. https://www.gsk.com/media/alvmln3q/final-2-_bepi_us_approval_sea_201026.pdf
- [Coverage] HCPLive, October 20, 2026. https://www.hcplive.com/view/fda-approves-bepirovirsen-for-chronic-hepatitis-b
- [Coverage] Pharmaceutical Executive, October 21, 2026. https://www.pharmexec.com/view/fda-approves-hibsago-bepirovirsen-chronic-hepatitis-b
6. Saroglitazar in MASH: steatohepatitis resolution without fibrosis worsening (EVIDENCES X)
[Clinical trial] [India; sites in the United States, Turkey, and Argentina]
The randomized, double-blind, placebo-controlled phase 2b EVIDENCES X trial (Zydus) assigned 189 patients with biopsy-proven MASH and F2–F3 fibrosis 1:1:1 to saroglitazar 2 mg, 4 mg, or placebo for 52 weeks. According to HCPLive coverage on November 6 of its presentation at The Liver Meeting 2026, MASH resolution without fibrosis worsening was 39.1% with 4 mg and 32.4% with 2 mg versus 13.7% with placebo (difference 24.9 percentage points with 4 mg; 95% CI, 9.5–40.3; P = .002). Fibrosis improvement by at least one stage (34.8% with 4 mg, 22.8% with 2 mg, and 24.6% with placebo) did not differ significantly from placebo at either dose. Saroglitazar remains an investigational treatment for MASH.
Why it matters: it is an oral PPAR alpha/gamma agonist and the trial included Argentine sites; however, the sample is small, the trial is manufacturer-sponsored, and it missed the secondary endpoint of fibrosis improvement, which is what drives prognosis.
Sources
- [Coverage] HCPLive, November 6, 2026. https://www.hcplive.com/view/saroglitazar-resolves-mash-without-fibrosis-worsening-evidences-x
- [Coverage] Medical Dialogues, November 8, 2026. https://medicaldialogues.in/news/industry/pharma/zydus-saroglitazar-shows-promising-phase-2b-results-in-mash-patients-182936
7. Primary biliary cholangitis: alkaline phosphatase normalization with elafibranor (ELSPIRE) and seladelpar (IDEAL)
[Clinical trial] [Multinational]
Two phase 3 trials in patients with primary biliary cholangitis and alkaline phosphatase above the upper limit of normal but below 1.67 times that limit despite ursodeoxycholic acid (or intolerant to it) measured different endpoints. ELSPIRE (elafibranor; 92 patients randomized 2:1), published in Hepatology on November 5: 85.3% reached normal alkaline phosphatase at week 52 versus 23.3% with placebo. IDEAL (second-line seladelpar; 96 patients), released by Gilead on November 5 and scheduled at The Liver Meeting for November 8: 75.4% (49/65) versus 16.1% (5/31) met the composite endpoint of normal alkaline phosphatase plus a decrease of at least 15% from baseline at week 52.
Why it matters: it supports aiming for normalization rather than mere "response" in patients with mild incomplete response, but alkaline phosphatase normalization is a surrogate endpoint, both trials are manufacturer-sponsored, and their different endpoints and designs do not allow the two drugs to be compared.
Sources
- [Official release] AASLD, November 5, 2026 (announces publication of ELSPIRE in Hepatology, DOI: 10.1097/HEP.0000000000001906). https://www.aasld.org/phase-iii-elspire-trial-results-published-hepatology-demonstrates-elafibranor-achieves-alp
- [Official release] Gilead, November 5, 2026. https://www.gilead.com/news/news-details/2026/positive-phase-3-ideal-study-results-further-support-livdelzis-seladelpar-impact-on-achieving-alp-normalization-goals-in-second-line-treatment-across-a-broad-population-of-people-living-with
- [Official release] Gilead, October 22, 2026. https://www.gilead.com/news/news-details/2026/gilead-to-present-new-data-on-treatment-response-and-long-term-management-of-rare-liver-diseases-at-the-liver-meeting-2026
- [Coverage] HCPLive, November 5, 2026. https://www.hcplive.com/view/elspire-elafibranor-achieves-alp-normalization-in-85-with-pbc
- [Coverage] HCPLive, November 5, 2026. https://www.hcplive.com/view/ideal-seladelpar-achieves-alp-normalization-in-second-line-pbc
8. ACG guideline on preventive care in cirrhosis
[Guideline] [United States] [Outside the period: October 5]
The ACG guideline, published online on October 5 in the American Journal of Gastroenterology, issues 18 recommendations and 6 key concept statements, with mostly low-certainty evidence. It strongly recommends carvedilol (cited dose 12.5 mg/day) or band ligation for primary prophylaxis of high-risk varices (the only moderate-certainty recommendation), ultrasound with alpha-fetoprotein every 6 months in candidates for hepatocellular carcinoma treatment, vaccination (hepatitis A, influenza, SARS-CoV-2, and RSV from age 50), and smoking-cessation counseling. It suggests carvedilol in compensated cirrhosis with clinically significant portal hypertension to prevent ascites, no aspirin or statins solely for chemoprevention, two to three days of antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeding, protein intake of 1.2–1.5 g/kg, and follow-up within 14 days of discharge.
Why it matters: it is a practical checklist applicable with basic resources in our setting (ultrasound, alpha-fetoprotein, vaccines, and carvedilol), although much of it rests on low-certainty evidence.
Sources
- [Article] Tapper EB, Kardashian A, Debes J, et al. "ACG clinical guideline: preventive care for patients with cirrhosis." Am J Gastroenterol. 2026. DOI: 10.14309/ajg.0000000000004186. https://doi.org/10.14309/ajg.0000000000004186
- [Coverage] HCPLive, October 6, 2026. https://www.hcplive.com/view/acg-guideline-sets-18-preventive-care-recommendations-for-cirrhosis
Endoscopy and pancreas–biliary tract
9. Fecal immunochemical testing (FIT) detects fewer cancers in women: sex-specific thresholds proposed
[Congress] [United States]
Retrospective analysis presented on October 13 at ACG 2026 of 30,165 participants from the DeeP-C and BLUE-C validation studies (163 colorectal cancers and 2,901 advanced precancerous lesions). At the comparator test's shared threshold of 100 ng/mL, FIT sensitivity for cancer was 77.4% in men versus 62% in women (P = .03) and for advanced lesions 25.8% versus 20.2% (P < .001). Thresholds yielding 95% specificity would be 120 ng/mL in men and 94 ng/mL in women; this is an exploratory estimate, not a validated clinical threshold.
Why it matters: it suggests lowering the threshold in women, but it is retrospective, uses a single FIT brand, and derives from studies designed for stool DNA tests; it does not change practice yet, though a negative FIT in a symptomatic woman does not rule out cancer.
Sources
- [Coverage] HMP Global Learning Network, October 13, 2026. https://www.hmpgloballearningnetwork.com/site/gastro/research/fit-crc-screening-performance-differs-sex
- [Coverage] Healio, October 16, 2026. https://www.healio.com/news/gastroenterology/20261016/equal-colorectal-cancer-detection-may-require-different-fit-thresholds-for-men-women
Esophagus, stomach, and microbiota
10. DETECT-ME: swallowable sponge with a DNA methylation panel to detect Barrett's esophagus
[Congress] [United States]
Prospective multicenter study (18 sites) presented at ACG 2026: 324 patients (181 with Barrett's esophagus) underwent cell collection with the EndoSign device (a capsule-encased sponge on a string) before reference endoscopy. Overall sensitivity was 90% and specificity 86%; sensitivity was 82% for short-segment, 99% for long-segment, and 100% (46/46) with dysplasia or adenocarcinoma. According to Healio's coverage, sensitivity was lower in the high-risk screening group (69%, versus 92% in patients with previously diagnosed Barrett's esophagus). Collection succeeded in 95%, with no device-related adverse events.
Why it matters: the population was enriched with known Barrett's esophagus, sensitivity in the real screening setting is clearly lower, and authors have industry ties; it does not replace endoscopy.
Sources
- [Coverage] Healio, October 14, 2026. https://www.healio.com/news/gastroenterology/20261014/methylation-test-tops-90-sensitivity-for-barretts-100-in-dysplasia-esophageal-cancer
- [Coverage] HCPLive, October 15, 2026. https://www.hcplive.com/view/detect-me-swallowable-sponge-test-for-barrett-s-esophagus-screening
Upcoming meetings and dates
- The Liver Meeting 2026 (AASLD) was held November 5–9 in Denver; ELSPIRE and IDEAL were scheduled to be presented there on November 8.
Ready-to-paste WhatsApp text
*Gastroenterology and hepatology bulletin — November 2026* Greetings, colleagues. Period: October 8 to November 7, 2026. 🔹 *IBD and functional disorders* *Oral icotrokinra in ulcerative colitis (ANTHEM-UC)* Response 63% vs 27% placebo at 12 weeks; in the extension, limited to week-28 responders, remission near 60% at 76 weeks. Phase 2b. https://www.healio.com/news/gastroenterology/20261021/oral-icotrokinra-sustains-uc-response-through-76-weeks-with-an-easier-sell-to-patients *FDA: subcutaneous risankizumab induction in Crohn's disease* AFFIRM: remission 56% vs 30% at 12 weeks, at home with an on-body injector. https://news.abbvie.com/2026-10-23-U-S-FDA-Approves-Subcutaneous-Induction-Regimen-for-AbbVies-SKYRIZI-R-risankizumab-rzaa-for-Adults-With-Moderately-to-Severely-Active-Crohns-Disease 🔹 *Liver* *FDA approves bepirovirsen for hepatitis B* Functional cure 19% vs 0% (suppressed HBV DNA and undetectable HBsAg 24 weeks after stopping all treatment). No cirrhosis, on antivirals, HBsAg ≤3000 IU/mL by an FDA-authorized test. https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment *Saroglitazar in MASH (EVIDENCES X)* Resolution without fibrosis worsening 39.1% vs 13.7%; no significant fibrosis improvement. Phase 2b, 189 patients with F2–F3 fibrosis. https://www.hcplive.com/view/saroglitazar-resolves-mash-without-fibrosis-worsening-evidences-x 🔹 *Endoscopy and screening* *FIT less sensitive in women* Cancer sensitivity 77.4% men vs 62% women at the shared 100 ng/mL threshold; the 120 and 94 ng/mL thresholds are an exploratory estimate, not validated. https://www.hmpgloballearningnetwork.com/site/gastro/research/fit-crc-screening-performance-differs-sex 🔹 *Esophagus* *Swallowable sponge for Barrett's (DETECT-ME)* Sensitivity 90%, specificity 86%; 69% in high-risk screening. https://www.healio.com/news/gastroenterology/20261014/methylation-test-tops-90-sensitivity-for-barretts-100-in-dysplasia-esophageal-cancer Full bulletin and audio: https://boletinesmedicos.com/en/gastroenterology/2026-11-07.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
Monthly gastroenterology and hepatology bulletin — November 7, 2026 10 verified items from ACG 2026, UEG Week 2026, The Liver Meeting 2026, NEJM, Hepatology, the American Journal of Gastroenterology, and FDA decisions. Three worth your time: • Bepirovirsen, FDA-approved for hepatitis B without cirrhosis: functional cure (suppressed HBV DNA and undetectable HBsAg 24 weeks after stopping all treatment) in 19% vs 0% with placebo (B-Well 1 and 2). One in five responds, and HBsAg quantification with an authorized test is required. • At-home subcutaneous risankizumab induction in Crohn's disease: clinical remission 56% vs 30% at week 12 (AFFIRM). Smaller benefit in patients with prior advanced therapy failure (45% vs 31%). • Oral icotrokinra in ulcerative colitis: clinical response 63% vs 27% at week 12 (NEJM) and, in the open-label extension limited to week-28 responders, remission near 60% at week 76. Phase 2b. Full bulletin, with a critical appraisal of each study and links to its sources: https://boletinesmedicos.com/en/gastroenterology/2026-11-07.html #Gastroenterology #Hepatology #HepatitisB #IBD #Cirrhosis
Ready-to-paste X (Twitter) post
FDA approves bepirovirsen for hepatitis B without cirrhosis: functional cure 19% vs 0%. Subcutaneous risankizumab induction in Crohn's: remission 56% vs 30%. Monthly GI and hepatology bulletin: https://boletinesmedicos.com/en/gastroenterology/2026-11-07.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.